These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 27425170)

  • 21. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
    Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M
    J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.
    Eghrari-Sabet J; Sher E; Kavati A; Pilon D; Zhdanava M; Balp MM; Lefebvre P; Ortiz B; Bernstein JA
    Allergy Asthma Proc; 2018 May; 39(3):191-200. PubMed ID: 29458456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months' Evolution and Prior Immunosuppressive Treatment.
    Cubiró X; Spertino J; Rozas-Muñoz E; Serra-Baldrich E; Puig L
    Actas Dermosifiliogr (Engl Ed); 2019 May; 110(4):289-296. PubMed ID: 30360885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic Idiopathic Urticaria.
    Wu EY; Saini SS
    J Allergy Clin Immunol Pract; 2015; 3(6):1003-4; quiz 105. PubMed ID: 26553623
    [No Abstract]   [Full Text] [Related]  

  • 25. Refractory solar urticaria successfully treated with omalizumab with normalization of phototest.
    Combalia A; Fernández-Sartorio C; Aguilera P
    Actas Dermosifiliogr; 2017; 108(6):593-594. PubMed ID: 28168968
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term omalizumab therapy for refractory chronic spontaneous urticaria: a real-life experience.
    Ensina LF; de Lacerda AE; Machado LM; Camelo-Nunes I; Solé D
    Ann Allergy Asthma Immunol; 2015 Dec; 115(6):536. PubMed ID: 26653279
    [No Abstract]   [Full Text] [Related]  

  • 27. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
    Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
    [No Abstract]   [Full Text] [Related]  

  • 28. Development of angio-oedema after omalizumab injections in a patient with chronic spontaneous urticaria.
    Magen E; Chikovani T
    Clin Exp Dermatol; 2018 Oct; 43(7):825. PubMed ID: 29777532
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum sickness-like reaction in a pediatric patient using omalizumab for chronic spontaneous urticaria.
    Eapen A; Kloepfer KM
    Pediatr Allergy Immunol; 2018 Jun; 29(4):449-450. PubMed ID: 29444344
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-term management of chronic spontaneous urticaria with omalizumab.
    Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
    Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey.
    Bulur I; Bulbul Baskan E; Ozdemir M; Balevi A; Kocatürk Göncü E; Altunay I; Gönül M; Ergin C; Ertam İ; Erdoğan HK; Bilgin M; Mustafa Teoman E
    Acta Dermatovenerol Alp Pannonica Adriat; 2018 Sep; 27(3):121-126. PubMed ID: 30244261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining Omalizumab with Another Biotherapy.
    Fougerousse AC; Becherel PA; Pallure V; Boyé T; Reguiai Z; Gabison G; Barthelemy H; Badaoui A; Mahé E; Livideanu CB;
    Acta Derm Venereol; 2019 Apr; 99(4):448-449. PubMed ID: 30723874
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials.
    Goldstein S; Gabriel S; Kianifard F; Ortiz B; Skoner DP
    Ann Allergy Asthma Immunol; 2017 Apr; 118(4):500-504. PubMed ID: 28390587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies.
    Zazzali JL; Kaplan A; Maurer M; Raimundo K; Trzaskoma B; Solari PG; Antonova E; Mendelson M; Rosén KE
    Ann Allergy Asthma Immunol; 2016 Oct; 117(4):370-377.e1. PubMed ID: 27424128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of omalizumab in severe solar urticaria.
    de Dios-Velázquez Á; González-de Arriba M; Beteta-Gorriti V; Macías E; Campanón-Toro V; Dávila I
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):260-2. PubMed ID: 26803538
    [No Abstract]   [Full Text] [Related]  

  • 36. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
    Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
    J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omalizumab: what benefits should we expect?
    Giménez-Arnau A; Velasco M; Armario Hita JC; Labrador-Horrillo M; Silvestre Salvador JF
    Eur J Dermatol; 2016 Aug; 26(4):340-4. PubMed ID: 27210073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
    Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
    Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.